Cytochrome P450 enzymes mechanism based inhibitors: Common sub-structures and reactivity

被引:140
作者
Fontana, E
Dansette, PM
Poli, SM [1 ]
机构
[1] Addex Pharmaceut SA, ADME PK Dept, CH-1228 Plan les Ouates, GE, Switzerland
[2] F Hoffmann La Roche Ltd, Pharmaceut Res, Discovery DMPK, CH-4070 Basel, Switzerland
[3] Univ Paris 05, CNRS, UMR 8601, F-75270 Paris, France
关键词
cytochrome P450; mechanism-based inhibitors;
D O I
10.2174/138920005774330639
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The inhibition of human cytochrome P450s (CYPs) is one of the most common mechanisms which can lead to drug-drug interactions. The inhibition of CYPs can be reversible (competitive or non-competitive) or irreversible. Irreversible inhibition usually derives from activation of a drug by CYPs into a reactive metabolite, which tightly binds to the enzyme active site, leading to a long lasting inactivation. This process is called "mechanism based inhibition" or "suicide inhibition". The irreversible inactivation usually implies the formation of a covalent bond between the metabolite and the enzyme, which can lead to hapten formation and can in some cases trigger an auto immune-response. For these reasons it is of utmost importance to study the mechanism of the CYP inhibition of new potential drugs as early as possible during the drug discovery process. The literature on CYPs is vast and covers numerous aspects of their biology and biochemistry, however to our knowledge there is no general and systematic review focusing on mechanism-based inhibitors; we have reviewed the literature and compiled all the available data on chemical entities, which are known to be CYP suicide inhibitors. Each compound is reported together with its chemical structure, the CYP isoform and the parameters describing the inactivation. Literature references are reported together with their PMID (PubMed ID number) to allow a fast retrieval of the papers. This review offers a quick reference to help predict liabilities of new chemical entities without carrying out extensive in vitro work, and will hopefully help in designing safer drugs.
引用
收藏
页码:413 / 454
页数:42
相关论文
共 192 条
[1]   Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol [J].
Alvarez-Diez, TM ;
Zheng, J .
CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (02) :150-157
[2]   1,2,3-Thiadiazole: A novel heterocyclic heme ligand for the design of cytochrome P450 inhibitors [J].
Babu, BR ;
Vaz, ADN .
BIOCHEMISTRY, 1997, 36 (23) :7209-7216
[3]   Mechanism-based inhibition of mouse P4502b-10 by selected arylalkynes [J].
Beebe, LE ;
Roberts, ES ;
Fornwald, LW ;
Hollenberg, PF ;
Alworth, WL .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (10) :1507-1513
[4]   Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine [J].
Bertelsen, KM ;
Venkatakrishnan, K ;
Von Moltke, LL ;
Obach, RS ;
Greenblatt, DJ .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :289-293
[5]   P450 active site architecture and reversibility:: Inactivation of cytochromes p450 2B4 and 2B4 T302A by tert-butyl acetylenes [J].
Blobaum, AL ;
Harris, DL ;
Hollenberg, PF .
BIOCHEMISTRY, 2005, 44 (10) :3831-3844
[6]   Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes:: Characterization of reactive intermediate adducts to the heme and apoprotein [J].
Blobaum, AL ;
Kent, UM ;
Alworth, WL ;
Hollenberg, PF .
CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (12) :1561-1571
[7]   α-naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6 [J].
Boek-Dohalská, L ;
Hodek, P ;
Sulc, M ;
Stiborová, M .
CHEMICO-BIOLOGICAL INTERACTIONS, 2001, 138 (01) :85-106
[8]  
BONDON A, 1989, J BIOL CHEM, V264, P1988
[9]   Characterization of cytochrome P450 3A inactivation by cannabidiol: Possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator [J].
Bornheim, LM ;
Grillo, MP .
CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (10) :1209-1216
[10]   CHARACTERIZATION OF CANNABIDIOL-MEDIATED CYTOCHROME-P450 INACTIVATION [J].
BORNHEIM, LM ;
EVERHART, ET ;
LI, JM ;
CORREIA, MA .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1323-1331